Difference between revisions of "Profiles"
Jump to navigation
Jump to search
m |
m (bold text) |
||
| Line 6: | Line 6: | ||
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Technically Confirmed Profiles=== | ===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Technically Confirmed Profiles=== | ||
| − | *[[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf | MR Elastography of the Liver 2022-02-14]] | + | *[[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf| MR Elastography of the Liver 2022-02-14]] |
| − | * [[Media: | + | * [[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2018.11.18-clean-3.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18]] |
| − | * [[Media: | + | * [[Media:QIBA CTVol TumorVolumeChangeProfile TechConfirmed-20180622a.pdf|CT Tumor Volume Change for Advanced Disease (CTV-AD) 2018-06-22]] |
:* Conformance Checklists (refer to Appendix C in the Profile document - pg 42) | :* Conformance Checklists (refer to Appendix C in the Profile document - pg 42) | ||
:* Assessment Procedures (refer to Section 4 in the Profile document - pg 30) | :* Assessment Procedures (refer to Section 4 in the Profile document - pg 30) | ||
| − | * [[Media: | + | * [[Media:QIBA FDG-PET Profile v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]] |
| − | :* [[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]] | + | :*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]] |
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles=== | ===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles=== | ||
| − | *[[Media: | + | *[[Media:QIBA CTA Profile as of 2020-Mar-10.pdf| CTA Atherosclerosis 2020-03-10]] |
| − | :*[[Media: | + | :*[[Media:QIBA CTA Field Test Checklist.xlsx| CTA Atherosclerosis Checklist 2020-05-28]] |
| − | *[[Media: | + | *[[Media:QIBA CT Lung Density Profile 090420-clean.pdf| CT Lung Density Profile_09.04.2020, clean version]] (Contains Conformance Checklist, Appendix B) 2020-10-23 |
| − | :*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Appendix E:CT Lung Density Protocols 2019-06-26]] | + | :*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Appendix E:CT Lung Density Protocols 2019-06-26]] |
*[[Media:DCE-MRI Quantification Profile v1.0.pdf| MR DCE Quantification v1.0 2012-08-08]] | *[[Media:DCE-MRI Quantification Profile v1.0.pdf| MR DCE Quantification v1.0 2012-08-08]] | ||
| − | *[[Media: | + | *[[Media:QIBA DWIProfile Consensus Dec2019 Final.pdf| MR Diffusion-Weighted Imaging (DWI) 2019-12-20]] |
| − | *[[Media: | + | *[[Media:QIBA DSC-MRI Stage2-Consensus Profile.pdf| MR Dynamic Contrast Susceptibility (DSC) 2020-10-22]] |
| − | *[[Media:MRE-QIBAProfile-2018-05-02-CONSENSUS.pdf | MR Elastography of the Liver 2018-05-02]] | + | *[[Media:MRE-QIBAProfile-2018-05-02-CONSENSUS.pdf| MR Elastography of the Liver 2018-05-02]] |
| − | *[[Media: | + | *[[Media:QIBA Profile MSK-Cartilage-Stage2 Profile.pdf| MR MSK cartilage for joint disease 2021-09-25]] |
| − | *[[Media: | + | *[[Media:QIBA AmyloidPET 20June2018 consensus.pdf| PET F-18 for Amyloid 2018-06-20]] |
| − | *[[Media:001. | + | *[[Media:001.QIBA SPECT Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf| SPECT Ioflupane for Neurodegenerative Disease v1.1, 2017-06-26]] |
| − | *[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf | SPECT Ioflupane for Neurodegenerative Disease v2.0, 2019-10-15]] | + | *[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf| SPECT Ioflupane for Neurodegenerative Disease v2.0, 2019-10-15]] |
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]] | :*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]] | ||
| − | *[[Media: | + | *[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]] |
| − | *[[Media: | + | *[[Media:QIBA US SWS Profile 04.25.2022-clean version.pdf|US Shear Wave Speed for Liver Fibrosis-2022-04-25]] ('''closed''' on May 3, 2022) |
:*[[Media:SWS Checklists-Appendix E-04.25.2022.xlsx|Appendix E: SWS Checklists]] (updated April 25, 2022) | :*[[Media:SWS Checklists-Appendix E-04.25.2022.xlsx|Appendix E: SWS Checklists]] (updated April 25, 2022) | ||
| + | ===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles === | ||
| − | + | '''Please submit comments using the '''[https://forms.gle/bPzUAuLKJnHYGbVS7 '''online form'''] | |
| − | + | *[[Media:QIBA DCE-MRI Profile-Stage 1-Public Comment.pdf|MR DCE-MRI Quantification (DCEMRI-Q) 2020-10-12]] ('''closed''' on March 10, 2021) | |
| − | *[[Media: | + | *[[Media:QIBA Profile MSK-Cartilage-Stage1 Profile.pdf|MR MSK cartilage for joint disease 2020-05-18]] ('''closed''' on October 29, 2020) |
| − | *[[Media: | + | *[[Media:QIBA US SWS Profile 10.21.19.pdf|US Shear Wave Speed for Liver Fibrosis 2019-10-21]] ('''closed''' on December 18, 2019) |
| − | |||
| − | |||
:*[[Media:SWS Checklists-Appendix E.xlsx|Appendix E: SWS Checklists, 2019-10-21]] ('''closed''' on December 18, 2019) | :*[[Media:SWS Checklists-Appendix E.xlsx|Appendix E: SWS Checklists, 2019-10-21]] ('''closed''' on December 18, 2019) | ||
| − | *[[Media: | + | *[[Media:QIBA fMRI Profile 1 PC-rev1.pdf| fMRI for Sensorimotor Mapping 2017-06-19]] ('''closed''' on December 31, 2017) |
| − | '''[[Comment Resolutions]]''' <font color=black>are posted for '''Past Public Comments''' and '''Past Technical Confirmations'''. | + | '''[[Comment Resolutions]]''' <font color="black">are posted for '''Past Public Comments''' and '''Past Technical Confirmations'''. |
| Line 70: | Line 69: | ||
Cite QIBA Profile documents as: | Cite QIBA Profile documents as: | ||
| − | : ''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Version. Profile Stage''. ''Date''. Available from: ''URL'' | + | :''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Version. Profile Stage''. ''Date''. Available from: ''URL'' |
Example: | Example: | ||
| − | : QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles | + | :QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles |
| Line 83: | Line 82: | ||
| − | ====See Also==== | + | ==== See Also==== |
*[[How to use QIBA Profiles]] | *[[How to use QIBA Profiles]] | ||
*[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage. | *[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage. | ||
Revision as of 19:37, 6 May 2022
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Profiles may be of use at any Stage.
Stage 3: Technically Confirmed Profiles
- Conformance Checklists (refer to Appendix C in the Profile document - pg 42)
- Assessment Procedures (refer to Section 4 in the Profile document - pg 30)
Stage 2: Consensus Profiles
- CT Lung Density Profile_09.04.2020, clean version (Contains Conformance Checklist, Appendix B) 2020-10-23
- US Shear Wave Speed for Liver Fibrosis-2022-04-25 (closed on May 3, 2022)
- Appendix E: SWS Checklists (updated April 25, 2022)
Stage 1: Public Comment Profiles
Please submit comments using the online form
- MR DCE-MRI Quantification (DCEMRI-Q) 2020-10-12 (closed on March 10, 2021)
- MR MSK cartilage for joint disease 2020-05-18 (closed on October 29, 2020)
- US Shear Wave Speed for Liver Fibrosis 2019-10-21 (closed on December 18, 2019)
- Appendix E: SWS Checklists, 2019-10-21 (closed on December 18, 2019)
- fMRI for Sensorimotor Mapping 2017-06-19 (closed on December 31, 2017)
Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.
Format for Citing Profiles
Cite QIBA Profile documents as:
- Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Version. Profile Stage. Date. Available from: URL
Example:
- QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)